Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns.
Petit PR, Touret F, Driouich JS, Cochin M, Luciani L, Bernadin O, Laprie C, Piorkowski G, Fraisse L, Sjö P, Mowbray CE, Escudié F, Scandale I, Chatelain E, de Lamballerie X, Solas C, Nougairède A.
Petit PR, et al. Among authors: mowbray ce.
Heliyon. 2024 May 8;10(10):e30862. doi: 10.1016/j.heliyon.2024.e30862. eCollection 2024 May 30.
Heliyon. 2024.
PMID: 38803975
Free PMC article.